RecentTrendsandChangesinR&D/BDamongKorean

biopharmasJamesJungkueLee

BridgeBiotherapeutics,Inc

BioKorea 2016

1

Opening

• Koreabiopharma industryhasundergoneprofoundchangesin2015/6season,30yearsafterKoreagovernmentamendedpatentlawtoimplementCOM(compositionofmatter)patentin1987.Hanmi’s stringsofsuperdealsin2015hasraisedthelevelofself-confidenceacrossKoreabiopharma industryandhasmadeex-Koreabiopharma industryplayersconsiderKoreaemergingandprovensourceofinnovations.Insuchinternalandexternalchanges,pharmas andbiotechs hascautiouslyintroducedchangesintoitsR&DandBDstrategy.Thispresentationwilltrytorecapsuchchangesinlast12monthsandsuggestseveralrecommendationstoKoreanandex-Koreanbiopharma.

2

BridgeBiotherapeutics,Inc.

• Virtuallyoperatingbiotech• Anoveltargetbiologywithpotentialformultiple

indications• IND-enablingGLPstudywillbeinitiatedinH2,2016

3

KoreanBiopharma industry-Genesisü1988• Adoptionof”COM”patent• NCEdiscovery(mostlyme-tooapproach)started

ü1997• Firstwaveoflicensing-outtobigpharma• LGLifeSciences,Yuhan,SKCorp

4

KoreanBiopharma industry-Genesis

5

KoreanBiopharma industry-Genesis

6

KoreanBiopharma industry-Growthü1999/2000• >200biotechstartups• Traditionalpharmas startedNCE/NMEresearch

ü2015• Hanmi Pharma’sserialhome-rundeals

7

KoreanBiopharma industry-Growth

8

KoreanBiopharma industry- Now

üVCindustryisgettingsmarter.• Moreexperiencedventurecapitals• Fundsizehasincreased

üAcademiacontinuestobringnovelsciences• Maturescience• Professor/academicresearchersstartedtorespectindustry

üIndustry• Hungerfornoveltyduetocontinuedfailurewith“me-too”approach

9

KoreanBiopharma industry- NowandNearFuture

10

CurrentTrends

üBiotechsectorisgettingmature.• Moreclinicalstageassetsbeingdevelopedglobally• SeasonedentrepreneurandBDexecutives• Experiencedventurecapitals

üNovelsciencesspringoutfromacademia• Newwaveofstartupsfromacademiaorestablishedcompanies

üBiotechs aregettingvirtualized• Ecosystemisgettingmaturetosupportvirtualbiotechs.

11

CurrentTrends- Virtualization

• SkilledManagement• Seasonedventure

capital• Vendornetwork

(regionalandglobal)• Cutting-edgescience

12

CurrentTrends– Novelscience

• Hanmi- thelastsuccessof“me-tooorme-better”approach?

• Noveltargets• Strongandproprietary

biology

13

CurrentTrends– BDexpertise

• ExperiencedBDexecutive,home-grownandexpats

• Moreoptionsandflexibilitiesindealstructures

14

BridgeBiotherapeutics

• Internalteam:3+• TargetBiology:Pellino-1,validatedbySKKU• Asset:BBT-401(PPI),optimizedbyKRICT• Indication:IBD+• Collaborationnetwork• Universities– KoreanandUK• CRO– Korean,ChinaandUS• Collaborationnetwork

• Clinicaldevelopment:USINDfilingaimedat2H,2017

15

Qurient Therapeutics

• Aspin-offfromInstitut Pasteur Korea

• Semi-virtualoperationwithstrongPMcapability

• OneP2assetinUSAforatopicdermatitis,discoveredbydrugrepurposing

• OneP1assetinUSA,orphandrugdesignatedbyUSFDAforthetreatmentofTB.

• KOSDAQIPOthisyear

16

Oscotec/Genosco

• Genosco (Boston,US)isaspin-offfromOscotec.

KOSDAQ-tradedKoreancorporation.

• EstablishedasUScorporationinBoston

• Semi-virtualoperation

• Twoassets(SYKi andFLT3i)areatP1inUSA

17

ImmunoMet TherapeuticsInc

• Aspin-offfromHanall BioPharma withIND-ready

assetincancermetabolismspace.

• UScorporation,headquarteredinBoston.

• LaboratorieslocatedatJLAB,Houston,Texas.

• SeriesAof$5mcompletedrecently.

18

BiotechA

• Aspin-offfromaprestigiousuniversity.

• UniversityTLOhasminorbutmeaningfulequity

position.

• Novelbiology(GPCRandCNS)withpotential

indicationsforhigh-unmetneedsCNSdiseases

• Scientificfoundervs.managementteam

19

Yuhan Corp.

• Veryactiveinopeninnovationtoovercome

relativelyweakinternalcapability

• ImmuneOncia Therapeutics,LLC,Jointventure

withSorrent Therapeutics,US-basedbiotech

• Regionalrightforthefirstassetandglobalrightfor

thefollowingassets

20

ImplicationstoBD

• Activepre-marketingatvariousinternationalpartneringevents(JPMorgan,BIO,BioEurope etc)

• IncreasingnumberofbigpharmacompaniesseekingKoreaninnovationsveryactivelyandacoupleofthemtrytogetlocal.

• Koreanpharmacompanies(eg.,Hanmi,DongA,Yuhan,BuKwang andetc.)aresettingupCVCfunctioninternallyorexternally.

21

Koreanbiopharma industry,activeparticipantsinglobalbiophamaindustryasinnovationsources

22

23

JamesJunkue LeeCEO,BridgeBiotherapeutics,Inc.James.Lee@Bridgebiorx.com